Organisation paid for research Program year 2025 Source: CMS Open Payments

Northside Hospital Inc

Neither a doctor nor a teaching hospital

Research payments

$2,558,653

246 payments

Through program year 2025, Northside Hospital Inc is reported as receiving $2,558,653 in research payments, across 246 payments.

By program year

7 rows
Year Kind Amount Payments
2025 Research $819 1
2024 Research $13,304 5
2023 Research $3,275 3
2022 Research $121,843 14
2021 Research $419,267 54
2020 Research $969,559 93
2019 Research $1,030,586 76

Breakdown

Who paid Research payments · program years 2019–2025
  1. Jazz Pharmaceuticals Inc. $861,481 30 payments
  2. Pfizer Inc. $373,451 75 payments
  3. Eli Lilly and Company $289,706 10 payments
  4. GlaxoSmithKline, LLC. $242,625 51 payments
  5. Deciphera Pharmaceuticals Inc. $238,868 5 payments
  6. Celgene Corporation $173,581 6 payments
  7. TESARO, Inc. $133,888 7 payments
  8. Ucb SA $130,284 32 payments
  9. Astellas Pharma Global Development $36,740 18 payments
  10. Merck Sharp & Dohme Corporation $35,286 1 payment
Studies the money was for Research payments · program years 2019–2025
  1. A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of Cpx-351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies (Cpx351-102) $390,655 8 payments
  2. A Phase 1 Trial to Evaluate the Potential Impact of Renal Impairment on the Pharmacokinetics and Safety of CPX -351 (Daunorubicin and Cytarabine) Liposome for Injection Treatment in Adult Patients With Hematologic Malignancies $285,467 2 payments
  3. Invictus A Phase 3 Interventional Double-Blind Placebo-Controlled Study to Assess the Safety and Efficacy of Dcc-2618 in Patients With Advanced Gastrointestinal Stromal Tumors Who Have Received Treatment With Prior Anticancer Therapies $234,990 2 payments
  4. A Randomized, Open-Label, Phase 3 Study of Abemaciclib Combined With Standard Adjuvant Endocrine Therapy Versus Standard Adjuvant Endocrine Therapy Alone in Patients With High Risk, Node Positive, Early Stage, Hormone Receptor Positive, Human Epidermal Receptor 2 Negative, Breast Cancer $176,902 3 payments
  5. A Phase 2 Study to Evaluate Safety and Antitumor Activity of Avelumab in Combination With Talazoparib in Patients With Brca Or Atm Mutant Tumors $175,965 39 payments
  6. A Phase I Open Label Study to Evaluate the Safety Pharmacokinetic Pharmacodynamic and Clinical Activity of Pf06863135 A Bcell Maturation Antigen Bcmacd3 Bispecific Antibody in Patients With Relapsedrefractory Advanced Multiple Myeloma MM $132,653 4 payments
  7. A Phase 3, Randomized, Double-Blind, Multicenter Study of Dostarlimab $109,276 15 payments
  8. Expanded Access Protocol (EAP) of patients receiving nonconforming lisocabtagene maraleucel that is out of specification (OOS) for commercial release (JCAR017-NHL-001) $108,253 1 payment
  9. A Phase 1B Trial of Cpx-351 Lower Intensity Therapy (Lit) Plus Venetoclax As First Line Treatment for Subjects With Aml Who Are Unfit for Intensive Chemotherapy $76,218 2 payments
  10. A Phase 3, Randomized, Double-Blind, Placebo-Controlled, Multicenter Study Evaluating the Efficacy and Safety of Bimekizumab in Study Participants With Moderate to Severe Hidradenitis Suppurativa $75,661 31 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record